A Phase II Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

Trial Profile

A Phase II Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Cytomegalovirus-specific T-cell therapy Atara/MSKCC (Primary)
  • Indications Cytomegalovirus infections
  • Focus Therapeutic Use
  • Sponsors Atara Biotherapeutics
  • Most Recent Events

    • 27 Feb 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.
    • 03 Dec 2016 Interim results (n=15) published in an Atara Biotherapeutics media release.
    • 03 Nov 2016 According to an Atara Biotherapeutics media release, results from this trial will be presented at 58th American Society of Hematology (ASH) Annual Meeting 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top